Nasopharyngeal carcinoma (NPC) is prevalent in southern China, Southeast Asia and North Africa, with the undifferentiated type linked to the Epstein-Barr virus being the most common. It typically presents at an advanced stage (T3-T4, N2-N3) and is effectively treated with precision radiotherapy techniques like intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy and TomoHelical™. These methods provide precise radiation delivery while minimizing dose to critical organs. The TomoTherapy® System offers benefits in target volume coverage and reduced radiation to adjacent organs, making it particularly advantageous for treating locoregionally advanced NPC. This presentation will cover its epidemiology, treatment strategies and experiences.